Recently, G1945V referred to a SH post re: how BP selects new drugs to develop and market. The article was a broad brush overview of the process but quoted a Pfizer exec who indicated it was the most difficult thing they do - selecting the blockbusters of the future from the crowded list of drugs in development. If they wait too long and regulatory approval is imminent, all 17 BP competitors will be standing in line and the game is over. If they commit too soon, the costs will be high and the odds for approval will be low - a crap shoot of the highest order.

BDAZ referred to slide 21 in the recent corporate RVX update which announced that RVX is actively pursuing FDA approval which is key to lifting the shadow over RVX-208 and general acceptance of this new science.

Slides 15,16 and 17 of the same presentation offer a clear picture of how RVX-208 works and why it is different then other approaches - Apabetalone modulates the Complement Pathway.

Last year RVX announced the restructuring which isolated RVX-208 and other CVD molecules and potential products and stripped away Zenith and it's potential cancer therapies and created the royalty preferred shares.

When the Board restructured, what were the motives? To isolate RVX-208 for tha Hepa partnership? To create a myriad of opportunities for thousands of compounds ? To separate CVD and Cancer therpies? To create a royalty revenue stream for clinical testing of Zenith cancer therapies? To create an opportunity for KD and others rewarding them for their PP's? I'm not sure that they are totally comfortable with the restructuring and the capitalization of Zenith - and where this goes from here.

If BP does want to roll the dice, do they want the full platform or will they be satisfied with RVX-208? And at what cost? Slide 30 (2-8 billion) for RVX-208.

There are numerous issues in play here and multiple opportunities for all.

Tepidly awaiting the Zenith update on Monday, but more importantly I look forward to the release of the annual reports which may shed new light on probability of revenue streams, cash flows, capital structure, future corporate plans, etc. and anxiously await trial results and futility analysis

The catalysts are out there - we are getting closer - this could explode soon.

Long and Strong

Chicagoest